Remote Monitoring in Young Adults With Inflammatory Joint Disease
Key facts
- Who runs it
- Diakonhjemmet Hospital
- Where
- Norway1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 148 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Remote digital follow-up
- Conventional hospital-based follow-up
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 30 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Biological male or female aged 18-30 years at the time of informed consent
- Clinical diagnosis of JIA, RA, SpA, or PsA
- Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted
- Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS< 2.1, DAPSA≤14)
- Ability to understand Norwegian
- Capable of providing written informed consent
- Access to a smartphone or tablet compatible with installation of the Dignio application
Who cannot take part
- Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis
- Indications of active tuberculosis (TB)
- Stills disease (systemic JIA)
- Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible
- Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2
- Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis
- Pregnant and/or breastfeeding
- Currently enrolled in a different RCT
- Leukopenia and/or thrombocytopenia
- Planned pregnancy during the study period
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 30 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.
Read full original descriptionShow less
The main questions it aims to answer are:
* Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months? * Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)
Participants will:
* Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital . * Complete questionnaires about their symptoms, health, and treatment during the study. * Attend appointments with a rheumatologist at the start of the study and at study end at 24 months. * If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform. * If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.
This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .
The 2 groups in the trial
- Remote digital follow-upTreatment being tested
Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment.
- Conventional hospital-based follow-upExisting treatment, for comparison
Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Remote Monitoring and Personalized Patient Pathways in Young Adults With Inflammatory Joint Disease (ReMonit Young)
- Criteria questions
- Built from NCT07937475, who can take part
- Record updated
- 16 November 2026